FY2025 Earnings Forecast for Omeros Issued By HC Wainwright

Omeros Co. (NASDAQ:OMER - Free Report) - Research analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Omeros in a note issued to investors on Tuesday, June 10th. HC Wainwright analyst B. Folkes anticipates that the biopharmaceutical company will earn ($1.78) per share for the year. HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Omeros' current full-year earnings is ($3.09) per share.

OMER has been the topic of several other research reports. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a research note on Friday, May 16th. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, May 13th. Finally, Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and an average price target of $18.00.

Omeros Stock Performance

Shares of NASDAQ:OMER traded down $0.07 during mid-day trading on Thursday, hitting $3.55. The stock had a trading volume of 650,004 shares, compared to its average volume of 687,986. The company has a market cap of $208.01 million, a PE ratio of -1.54 and a beta of 2.20. Omeros has a 12-month low of $2.97 and a 12-month high of $13.60. The company's 50 day moving average is $5.23 and its 200-day moving average is $7.85.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.05).

Institutional Trading of Omeros

Several large investors have recently modified their holdings of OMER. Nomura Holdings Inc. boosted its holdings in shares of Omeros by 136.2% during the 4th quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock worth $7,383,000 after buying an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in Omeros in the 4th quarter valued at $1,488,000. Wellington Management Group LLP bought a new stake in Omeros in the 1st quarter valued at $1,118,000. Nuveen LLC bought a new stake in Omeros in the 1st quarter valued at $938,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Omeros in the 4th quarter valued at $1,120,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.